Merz Therapeutics

Privately held: no public share price

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Fampridine(Ampyra / Fampyra)
Approved
Potassium Channel Blocker · Voltage-gated potassium channel (Kv) · Voltage-gated potassium channels (Kv1/Shaker/KCNA family)Small molecule
Multiple Sclerosis
Approved
dopamine precursorSmall molecule
Parkinson's Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.